Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berberine for Antipsychotic-induced Metabolic Syndrome in Schizophrenia
NCT02983188Phase 3Completed
- Sponsor
- The University of Hong Kong
- Start
- Apr 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic syndrome comparing Berberine with Placebo (2 arms). Primary endpoint: Changes in net weight gain at 12 weeks. Started Apr 2018; status: completed.
02
Drugs
berberine
03
Conditions
metabolic syndrome
Beyond the preview
Go deeper on NCT02983188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02983188.